Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer

September 28, 2026

SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Eiry W. Roberts, M.D., who previously served as Neurocrine's Chief Medical Officer and currently serves as a Strategic Advisor, will rejoin the Company's executive management team as Chief Medical Officer (CMO), effective immediately. By mutual agreement, Sanjay Keswani, M.D., will depart the Company.

Dr. Roberts served as Neurocrine's Chief Medical Officer from 2018 to 2025 and has continued to support the Company since that time as a Strategic Advisor. As CMO, Dr. Roberts led indication-expansion efforts for INGREZZA® and the crinecerfont development program that led to the U.S. Food and Drug Administration approval of CRENESSITY®. Before joining Neurocrine in 2018, Dr. Roberts spent 26 years at Eli Lilly and Company, where she held senior research and development roles, including Vice President, Research and Development. Dr. Roberts currently serves on the Board of Directors of Bausch Health Companies and previously served on the Board of Directors of Amicus Therapeutics until its acquisition by BioMarin Pharmaceutical in April 2026.

"We are pleased to welcome Eiry back to the Chief Medical Officer role. Her deep knowledge of Neurocrine, our pipeline and our clinical development programs provides strong continuity at a time when we are advancing multiple late-stage programs and preparing for several important clinical milestones," said Kyle W. Gano, Ph.D., President and Chief Executive Officer of Neurocrine Biosciences. "Our research and development priorities and our clinical programs are on track, and Eiry's experience with our portfolio positions her well to lead our clinical development efforts. I look forward to working closely with her once again. We thank Sanjay for his contributions to Neurocrine and wish him well in his next chapter."

"I am honored to assume the Chief Medical Officer role again and contribute to our mission of relieving suffering for people with unmet needs," Dr. Roberts said. "Having remained closely connected to the Company as a Strategic Advisor, I am excited about the opportunities ahead. I look forward to building on the teams' progress, advancing the portfolio, and ultimately delivering meaningful benefits for patients and value for shareholders."

About Neurocrine Biosciences

Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (**in collaboration with AbbVie*)

Forward-Looking Statements

In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the Company's ability to execute on its clinical development plans and the contributions Dr. Roberts may make in her role with the Company. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: challenges that the Company may encounter in implementing the leadership transition; risks and uncertainties associated with the Company's business and finances in general; risks and uncertainties associated with the commercialization of our products; risks related to the development of our product candidates; risks associated with our dependence on third parties for development, manufacturing, and commercialization activities for our products and product candidates, and our ability to manage these third parties; risks that the FDA or other regulatory authorities may make adverse decisions regarding our products or product candidates; risks that development activities may not be initiated or completed on time or at all, or may be delayed for regulatory, manufacturing, or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials; risks that the potential benefits of the agreements with our collaboration partners may never be realized; risks that our products, and/or our product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks associated with government and third-party regulatory and/or policy efforts which may, among other things, impose sales and pharmaceutical pricing controls on our products or limit coverage and/or reimbursement for our products; risks associated with competition from other therapies or products, including potential generic entrants for our products; risks associated with our ability to manage the growth of our organization; and other risks described in our periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2026. The Company disclaims any obligation to update the statements contained in this press release after the date hereof other than as required by law.

Neurocrine Biosciences, Inc.,Tony Jewell (Media), 858-617-7578, media@neurocrine.com; Todd Tushla (Investors), 858-617-7143, ir@neurocrine.com